Tracked deals
5
5 tracked deals across 2020-2025.
Marlborough, Massachusetts, United States
Innovative medical technology company focused on improving women’s health through early detection and treatment, with core areas across Breast & Skeletal Health, Diagnostic Solutions, and GYN Surgical Solutions.
Tracked deals
5
5 tracked deals across 2020-2025.
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
4 buyout · 1 addon
Last 4 years
Supporting Data
Hologic, Inc. completed its previously announced acquisition of Gynesonics, a privately held medical device company focused on minimally invasive solutions for women’s health, for about $350 million. Gynesonics develops the Sonata System for diagnostic intrauterine imaging and incision-less transcervical treatment of certain symptomatic uterine fibroids.
Hologic signed a definitive agreement to acquire Endomagnetics Ltd (Endomag), a Cambridge, United Kingdom-based developer of breast cancer surgical guidance technologies, for approximately $310 million. The deal is subject to customary closing conditions, including regulatory approvals, and Endomag’s wireless breast surgery localization and lymphatic tracing solutions are expected to complement Hologic’s breast surgery portfolio.
Maverix Medical, a lung cancer platform backed by Ajax Health, KKR, and Hologic, has acquired Cirrus Bio to form the foundation of a new diagnostics division, Maverix Dx. Cirrus Bio's multiomic diagnostic capabilities and its founders, David Mallery (CEO) and Scott Morris (CSO), will lead Maverix Dx as the platform pursues further diagnostic product development and M&A.
Hologic, Inc. has completed its previously announced acquisition of Bolder Surgical, a privately held U.S. provider of advanced energy vessel sealing surgical devices, for approximately $160 million. The deal expands Hologic’s surgical portfolio with laparoscopic vessel sealing, dividing and dissection tools and enables broader use of Bolder’s devices by OB/GYN specialists.
Hologic, Inc. has acquired Acessa Health Inc., a privately held maker of the Acessa ProVu minimally invasive system for treating uterine fibroids, for approximately $80 million in cash plus contingent payments. The tuck-in purchase expands Hologic's GYN surgical portfolio and leverages Hologic's commercial infrastructure to accelerate adoption of Acessa's technology.
Turn tracked acquisition activity into an outreach-ready buyer list.